<SEC-DOCUMENT>0001659617-19-000145.txt : 20190816
<SEC-HEADER>0001659617-19-000145.hdr.sgml : 20190816
<ACCEPTANCE-DATETIME>20190816171830
ACCESSION NUMBER:		0001659617-19-000145
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20190816
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190816
DATE AS OF CHANGE:		20190816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		191034209

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k63019earningsre.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:1B16267244CE5DF19AD25570F686B687,x:f08a84852bbd46c88c4777c8c6e1adc5-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:mbrx="http://www.moleculin.com/20190814" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2019Q3SD" name="dei:AmendmentFlag" id="Fact-FF67BFF477A671CFC2D88BB5B714C551-wk-Fact-FF67BFF477A671CFC2D88BB5B714C551" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q3SD" name="dei:EntityCentralIndexKey" id="Fact-1BB182FCC8EFE2752BCC8BB549360B06-wk-Fact-1BB182FCC8EFE2752BCC8BB549360B06">0001659617</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mbrx-20190814.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2019Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-16</xbrli:startDate>
			<xbrli:endDate>2019-08-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="s68E26531C0EA52EC9B90F6A57DC6E58E"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d3968466e93-wk-Fact-BFCCCD59C0DB907A9DD68B8898B81256" name="dei:DocumentType" contextRef="D2019Q3SD"><span style="font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d3968466e110-wk-Fact-335E36ED6114A3EF098697945A4E7BF0" name="dei:DocumentPeriodEndDate" contextRef="D2019Q3SD" format="ixt:datemonthdayyearen">August 16, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;"><img src="moleculin-logo_horiza03.jpg" alt="moleculin-logo_horiza03.jpg" style="height:48px;width:181px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d3968466e119-wk-Fact-C4D13C33BD86A112EF278B8A40761BD3" name="dei:EntityRegistrantName" contextRef="D2019Q3SD"><span style="font-weight:bold;">MOLECULIN BIOTECH, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d3968466e142-wk-Fact-D876CC2F066E8A9CDD0C8B8B3D88DBE8" name="dei:EntityIncorporationStateCountryCode" contextRef="D2019Q3SD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d3968466e147-wk-Fact-18E6E7AE14006870306F8B8B7C83F55B" name="dei:EntityFileNumber" contextRef="D2019Q3SD">001-37758</ix:nonNumeric></span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d3968466e152-wk-Fact-0B7AC34A141D86976BAB8B8BC12CE89B" name="dei:EntityTaxIdentificationNumber" contextRef="D2019Q3SD">47-4671997</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation or Organization)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Commission File No.)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d3968466e173-wk-Fact-E01AEC1750693A148DCC8B8CD136E90E" name="dei:EntityAddressAddressLine1" contextRef="D2019Q3SD"><span style="font-weight:bold;">5300 Memorial Drive</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d3968466e178-wk-Fact-C170B3D425448F1927EE8B8D22349C41" name="dei:EntityAddressAddressLine2" contextRef="D2019Q3SD"><span style="font-weight:bold;">Suite 950</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d3968466e183-wk-Fact-F002B16F19FFE4D0DE7E8B8E2105341A" name="dei:EntityAddressCityOrTown" contextRef="D2019Q3SD"><span style="font-weight:bold;">Houston</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> ,</span><span><ix:nonNumeric id="d3968466e188-wk-Fact-57270FDF7DA81601812C8B8E35D5ABEF" name="dei:EntityAddressStateOrProvince" contextRef="D2019Q3SD"><span style="font-weight:bold;">TX</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d3968466e193-wk-Fact-ABD734054327A766E1A48B8E47662411" name="dei:EntityAddressPostalZipCode" contextRef="D2019Q3SD"><span style="font-weight:bold;">77007</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of principal executive offices and zip code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d3968466e206-wk-Fact-D1503B64D913FBA947A48B8F4C5852BD" name="dei:CityAreaCode" contextRef="D2019Q3SD"><span style="font-weight:bold;">713</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d3968466e211-wk-Fact-4FA8854297B8F32F64CA8B8FB6060C92" name="dei:LocalPhoneNumber" contextRef="D2019Q3SD"><span style="font-weight:bold;">300-5160</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> (Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> (Former name or former address, if changed from last report)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">see </span><span style="font-family:inherit;font-size:10pt;">General Instruction A.2. below):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">[</span><span><ix:nonNumeric id="d3968466e234-wk-Fact-836A8E11FDADC5973A6A8BA16FC3308E" name="dei:WrittenCommunications" contextRef="D2019Q3SD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">[</span><span><ix:nonNumeric id="d3968466e243-wk-Fact-1610C2D8BA4212E5B3BE8BA18C6F9946" name="dei:SolicitingMaterial" contextRef="D2019Q3SD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">[</span><span><ix:nonNumeric id="d3968466e251-wk-Fact-35A648C7A9643729A4AD8BA1A1F302BB" name="dei:PreCommencementTenderOffer" contextRef="D2019Q3SD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">[</span><span><ix:nonNumeric id="d3968466e259-wk-Fact-D2D1EF654FD44F6B14708BA1BA93BA32" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2019Q3SD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerging growth company [</span><span><ix:nonNumeric id="d3968466e274-wk-Fact-1DC4D24253C6E897F2238BB69D203995" name="dei:EntityEmergingGrowthCompany" contextRef="D2019Q3SD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9746;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">]</span></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [</span><span><ix:nonNumeric id="d3968466e282-wk-Fact-F26AB43F0BE91CB21A658C470D9EFCAA" name="dei:EntityExTransitionPeriod" contextRef="D2019Q3SD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9746;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">]        Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:28%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Trading Symbol (s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d3968466e317-wk-Fact-EB0A622A2D08A339A3E58BA4B8ABEB86" name="dei:Security12bTitle" contextRef="D2019Q3SD">Common Stock, par value $.001 per shares</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d3968466e322-wk-Fact-35D5D1C56CCC9AAD50F68BA4FA6FD3D4" name="dei:TradingSymbol" contextRef="D2019Q3SD">MBRX</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d3968466e327-wk-Fact-E202F2E157FA5A6250428BA65A4B008C" name="dei:SecurityExchangeName" contextRef="D2019Q3SD" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s62993C981F355085B2FC481A73ACC715"></a></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 2.02  Results of Operations and Financial Condition.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:11pt;">On August 16, 2019, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended June 30, 2019 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit No.&#160;&#160;&#160;&#160;Description</span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="exh991-financials63019q220.htm"><span style="font-family:inherit;font-size:11pt;">99.1</span></a><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="exh991-financials63019q220.htm"><span style="font-family:inherit;font-size:11pt;">Press release dated August 16, 2019</span></a></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:justify;padding-left:192px;text-indent:-96px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SIGNATURE</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:48px;text-align:justify;padding-left:336px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">MOLECULIN BIOTECH, INC.</span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Date:  August 16, 2019</span></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jonathan P. Foster</span></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Jonathan P. Foster</span></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Chief Financial Officer  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"></span><span style="font-family:inherit;font-size:10pt;">2</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s97FBC4C0CB465478B835248BF4FCC3D8"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;-sec-extract:summary;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT INDEX</span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit No.</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Description</span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="exh991-financials63019q220.htm"><span style="font-family:inherit;font-size:11pt;">99.1</span></a><span style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="exh991-financials63019q220.htm"><span style="font-family:inherit;font-size:11pt;">Press release dated August 16, 2019</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"></span><span style="font-family:inherit;font-size:10pt;">3</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh991-financials63019q220.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s64FA94EE4EEC5F3695D282FE2A14FF61"></a></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="line-height:174%;text-align:left;"><img src="moleculin-logo_horiza03.jpg" alt="moleculin-logo_horiza03.jpg" style="height:60px;width:226px;"></div><div style="line-height:120%;text-align:center;font-size:20pt;"><font style="font-family:Calibri,sans-serif;font-size:20pt;color:#4472c4;font-weight:bold;">Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">HOUSTON, TX - August 16, 2019 - Moleculin Biotech, Inc., (NASDAQ: MBRX)</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended June 30, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Management Discussion</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Walter Klemp, chairman and chief executive officer of Moleculin, said, "The second quarter of 2019 exhibited significant progress in the various research initiatives and clinical trials that are underway on our drug candidates. During the quarter, we announced three important research developments that we believe can have meaningful impacts in successfully attacking certain rare and difficult cancers."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">"We recently announced an important discovery for the treatment of glioblastoma - one of the most common, and aggressive, types of malignant brain tumor among adults. In animal models, researchers at MD Anderson have combined our lead STAT3 inhibitor - WP1066 - with radiation therapy, the combination of which appears to have developed an immunological memory in immune-competent mice that enabled them to prevent regrowth of the tumor after these tumor cells were reintroduced. The result was the development of long-term survivors, leading to an increase in overall survival in these models. The median survival time with glioblastoma is 15 to 16 months in people who get surgery, chemotherapy, and radiation treatment. This is an important breakthrough that could have a profound impact in extending the lives of people afflicted with glioblastoma in the years to come."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">"The second important research development during the quarter," Mr. Klemp continued, "was the announcement of additional positive safety and efficacy data from our ongoing Phase 1/2 study - in Poland - of Annamycin for the treatment of acute myeloid leukemia, and consequently the advancement to our third cohort of patients to be treated. This third cohort of patients will be treated at a dose level of 180 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">. The previous two cohorts were treated at lower levels - 120 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;and 150 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">, respectively. We believe one of the most important unique attributes of Annamycin is its lack of cardiotoxicity, since all currently approved anthracyclines are significantly cardiotoxic (potential to damage the heart).  Importantly, we have seen no cardiotoxicity in any of the patients treated to date both in the US and in Europe. We believe this is an important pathway that may increase the opportunity for leukemia patients to qualify for potentially life-saving bone marrow transplants at a much higher rate than traditionally has been the case."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">"Our third important development during the quarter was the announcement that our ongoing sponsored research at The University of Texas MD Anderson Cancer Center resulted in the discovery that Annamycin, our lead drug candidate for the treatment of acute myeloid leukemia, has demonstrated - in animal models - an ability to significantly improve survival in triple negative breast cancer that has metastasized to the lungs. Annamycin has previously demonstrated a high uptake into the lungs in animal models. Triple-negative breast cancer is considered to be more aggressive and have a poorer prognosis than other types of breast cancer, mainly because there are fewer targeted medicines that treat triple-negative breast cancer. </font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 1</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Studies have shown that triple-negative breast cancer is more likely to spread beyond the breast and more likely to recur after treatment. With the demonstrated increased uptake into the lungs in animal models, we are excited about the possibilities for Annamycin in an expanding list of indications."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Mr. Klemp concluded, "From a strategic standpoint, we are highly focused on developing &#8216;multiple shots on goal&#8217; for the treatment of rare and difficult cancers. We are pleased with the progress being achieved in our research initiatives and clinical trials. We remain on track to deliver data from our ongoing clinical trials through the balance of the year."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Jonathan Foster, executive vice president and chief financial officer of Moleculin, stated, "From a financial standpoint we are in a strong position. We finished the second quarter with a solid balance sheet with cash of approximately $18.7 million and no debt. The strength of our balance sheet provides us the ability to fund our ongoing research programs and clinical trials. We believe our existing cash and cash equivalents will be sufficient to fund our planned operations well into 2020 without the issuance of additional equity for cash. We are focused on being capital efficient through our important developmental process."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 2</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Anticipated Milestones</font></div><div style="line-height:120%;padding-bottom:18px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:74%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Anticipated Milestones</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Potential Time Frame</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Next Generation Anthracycline - Annamycin</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical Trials - Complete cohort of 150 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;- prior trial recommended Phase II dose (RP2D)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;and ongoing 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Announcement of initial clinical data for Annamycin trial</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;and ongoing 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Announcement of RP2D for Poland Trial</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Poland clinical trial (MB-105) begins Phase II</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Approach FDA on U</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">S</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;trial (MB-104) on dose expansion using Poland trial data</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(Fast Track Approved)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Announce additional clinical research in lung and metastatic lung cancers</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Immune/Transcription Modulators - WP1066 Family</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Clinical Trials WP 1066 - Announcement of initial clinical data from WP1066 clinician sponsored trial</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Phase 1 surgical cohort begins</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Transfer clinician sponsored trial WP1066 IND to Moleculin</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Half of 2019</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emory Physician Led Pediatric Medulloblastoma Trial begins</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Half of 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Announcement of further benefits of our sponsored research agreement with MD Anderson</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">and ongoing 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical Trial WP1220 - Announce filing and approval of CTA for WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assess WP1220 initial patient data</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Q4-2019</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IND for WP1732 submitted</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dose first patient in Phase I trial for WP1732</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Announce further preclinical research results on WP1066 family</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;and ongoing 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Metabolism/Glycosylation Inhibitors</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Begin preclinical work on WP1122</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Complete formulation and begin manufacture of drug for trial</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Half of 2020</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">File IND for WP1122</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">General Clinical</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Announce a fourth approved clinical trial</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Accomplished</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Announce a fifth approved clinical trial</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Second Quarter Highlights and Recent Corporate Developments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;- </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">Data to be presented at the Inaugural Conference on Brain Metastases, August 16-17, 2019 </font><font style="font-family:Calibri,sans-serif;font-size:11pt;">-  August 6, 2019, the Company announced that a paper entitled "Immunological Reprogramming in the CNS Tumor Microenvironment and Therapeutic Efficacy of Radiotherapy with STAT3 Blockade" will be presented at the Inaugural Conference on Brain Metastases, in New York City, August 16-17, 2019. Dr. Martina Ott, of MD Anderson Cancer Center, will be presenting the findings of the research she conducted in collaboration with Dr. Amy Heimberger (the Principle Investigator of the current </font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 3</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">investigator-initiated clinical of WP1066 for brain tumors) in combining WP1066 with radiation therapy in glioblastoma animal models.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">One of the findings of her research that is especially encouraging is that immune-competent mice treated with both radiation and WP1066 developed an immunological memory that enabled them to prevent regrowth of the tumor after these tumor cells were reintroduced. The result was the development of long-term survivors, leading to an increase in overall survival in these models.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">This study was also particularly interesting because it showed the most robust immunological responses were located in the CNS (Central Nervous System) tumor microenvironment rather than peripheral non-tumor tissue.  Importantly, the study indicated that the combination of STAT3 inhibition with whole brain radiotherapy had the capacity to enhance the therapeutic effect against established tumors based on immunological competence.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort - </font><font style="font-family:Calibri,sans-serif;font-size:11pt;">July 18, 2019, the Company announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. Three patients were treated at a dose level of 150 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;with no drug-related adverse events, including no signs of cardiotoxicity. The results for all 3 patients were reviewed by the Drug Safety Review Committee, which determined that the trial could progress to the next higher dose level of 180 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">. To date in Poland, one patient experienced grade 2 mucositis (which resolved to grade 1 within 2 days) and no other adverse events related to Annamycin have been reported. One patient has completed treatment in the 120 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;(second) cohort in the Company's parallel US clinical trial (the US trial started at a lower initial dose of 100 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">). The Company continues to see no evidence of cardiotoxicity in any of the patients treated thus far in its clinical trials.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation - </font><font style="font-family:Calibri,sans-serif;font-size:11pt;">July 10, 2019, the Company announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin has Orphan Drug Designation in the US for the treatment of AML and the Company recently announced promising preclinical data showing the potential for Annamycin to become an important treatment for lung metastases. If these patent applications are approved, this will potentially give the Company 20 years of patent protection for Annamycin</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe - </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose level</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;- May 7, 2019, the Company announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. After receiving a single starting dose of 120 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;in the first cohort of the dose escalation phase of the trial, 2 of 3 patients treated responded sufficiently to qualify for a potentially curative bone marrow transplant. The results for all 3 patients were reviewed by the Safety Review Committee, which determined that no drug-related adverse events were observed that would prevent advancing the trial to the next higher dose level of 150 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">. To date in the European trial, one patient experienced grade 2 mucositis (which resolved to grade 1 within 2 days) and no other adverse events related to Annamycin have been reported. No additional patient data have been developed in the Company's parallel US clinical trial, which is currently recruiting its second cohort to be given a dose level of 120 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;(the U.S. trial started at a lower initial dose of 100 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces $15.0 Million Registered Direct Offering - </font><font style="font-family:Calibri,sans-serif;font-size:11pt;">April 23,2019, the Company announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of </font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 4</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering, which offering was closed on April 25, 2019. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock. Each warrant has an exercise price of $1.75 per share and is exercisable immediately. The warrants will expire five years from the date of issuance. The gross proceeds of the offering were approximately $15.0 million, prior to deducting the placement agent fees and other estimated offering expenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Receives FDA Approval of Fast Track Designation for Annamycin</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;- April 18, 2019, the Company announced that the FDA has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory AML.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">A drug that receives Fast Track designation is eligible for some or all of the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces Significant Discovery in Lung Cancer Models  - </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">Annamycin Found to be Active Against Metastases to the Lungs in Pre-Clinical Testing</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;- April 17, 2019, the Company announced that its ongoing sponsored research at The University of Texas MD Anderson Cancer Center has now demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models. The Company believes its success in increasing the survival rate in mice with this tumor model in combination with the previously observed high uptake of Annamycin by the lungs is a promising indication that supports additional clinical research in lung and metastatic lung cancers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;- April 11, 2019, the Company announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. The study will be conducted at the Aflac Cancer &amp; Blood Disorders Center at Children's Healthcare of Atlanta.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;- April 3, 2019, the Company announced that preclinical data supporting activity of its STAT3-inhibiting Immune/Transcription Modulators was presented by Dr. Waldemar Priebe, Founder and Chair of the Scientific Advisory Board of Moleculin, Inc. at the 2019 Annual Meeting of the American Association for Cancer Research in Atlanta, GA.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">AACR Abstract:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">https://www.moleculin.com/inhibition-of-stat3-in-pancreatic-ductal-adenocarcinoma-and-immunotherapeutic-implications/</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">The presentation included data resulting from preclinical evaluation in pancreatic cancer models of STAT3 inhibitors WP1066 and WP1732, both discovered at The University of Texas MD Anderson Cancer Center </font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 5</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">and licensed by Moleculin. WP1066 is an orally bioavailable drug with significant brain uptake that is currently in Phase 1 clinical studies in patients with brain tumors. Complementary to WP1066, we believe STAT3 inhibitor WP1732 may be suitable for IV administration and demonstrates high uptake by the pancreas without uptake to the brain.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Financial Results for the Second Quarter ended June 30, 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Research and Development Expense.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;Research and development ("R&amp;D") expense was $2.1 million and $4.2 million for the three months ended June 30, 2019 and 2018, respectively. The decrease of $2.1 million is mainly related to costs incurred in 2018 of producing additional drug product for the Company&#8217;s Annamycin clinical trials.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">General and Administrative Expense.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;General and administrative expense was $1.5 million and $1.2 million for the three months ended June 30, 2019 and 2018, respectively. The increase of $0.3 million was mainly attributable to an increase in G&amp;A related payroll costs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Gain from Change in Fair Value of Warrant Liability.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;We recorded a net gain of $2.4 million in the second quarter of 2019 as compared to a net gain of $0.3 million in the second quarter of 2018, for the change in fair value on revaluation of our warrant liability associated with our warrants issued in conjunction with our stock offerings in April 2019, March 2019, June 2018, February 2018, and February 2017. We are required to revalue certain warrants at the time of each warrant exercise and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculated the fair value of the warrants outstanding using the Black-Scholes model. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price.  During the quarter, our stock price fluctuated greatly.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">As of June 30, 2019, the Company had cash and cash equivalents of $18.7 million. In April 2019, the Company received gross proceeds of approximately $16.6 million, as a result of a completed public offering and the exercise of various warrants from past public offerings. This brings the Company&#8217;s total net cash raised through its financing efforts year to date to $20.8 million.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Cash used in operations was $9.2 million for the six months ended June 30, 2019. This $2.9 million increase over the prior year of $6.3 million was mainly due to preparing for clinical trials, an increase in R&amp;D payroll costs</font><font style="font-family:Times New Roman;font-size:11pt;">,</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;an increase in paid sponsored research and related expenses</font><font style="font-family:Times New Roman;font-size:11pt;">,</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#32;and an increase in license fees. These are all a reflection of the ongoing clinical and pre-clinical activity and the associated increase in G&amp;A support for our three core drug technologies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">The Company believes that its existing cash and cash equivalents as of June 30, 2019, will be sufficient to fund planned operations into the second quarter of 2020, without the issuance of additional equity for cash. Such issuances should extend the funding of the Company&#8217;s planned operations significantly beyond the second quarter of 2020. Such plans are subject to the Company&#8217;s stock price, market conditions, changes in planned expenses depending on clinical enrollment progress, the use of drug product or a combination thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 6</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">About Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the treatment of highly resistant cancers. Moleculin has three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center by Dr. Waldemar Priebe and his team. The Company&#8217;s clinical-stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. The Company is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors. Moleculin&#8217;s Next Generation Anthracycline, Annamycin, we believe, is unlike any currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients and is currently in two Phase I/II clinical trials. WP1066 is one of several Immune/Transcription Modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and</font><font style="font-family:Times New Roman;font-size:11pt;">&#32;HIF-1&#183;. These transcription factors </font><font style="font-family:Calibri,sans-serif;font-size:11pt;">are widely sought targets that may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors. Moleculin is also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis. The Company&#8217;s lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy (2-DG) within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">For more information about the Company, please visit </font><font style="font-family:Calibri,sans-serif;font-size:11pt;text-decoration:underline;">http://www.moleculin.com</font><font style="font-family:Times New Roman;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Moleculin to successfully recruit sufficient patients to complete its current clinical trials; the ability of Moleculin to file an IND for WP1732; the ability of Moleculin&#8217;s drug candidates to show safety and efficacy in patients; and the ability of Moleculin to receive patent protection for Annamycin. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.&#160; Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 7</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Contacts</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Joe Dorame, Robert Blum or Joe Diaz</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Lytham Partners, LLC</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">602-889-9700</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;text-decoration:underline;">mbrx@lythampartners.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">---Financial tables on the following page---</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:Times New Roman;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 8</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Moleculin Biotech, Inc.  </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Unaudited Condensed Consolidated Balance Sheets</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">18,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">7,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Prepaid expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">20,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">7,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Furniture and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">401</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">463</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">11,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">11,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Operating lease right-of-use asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total Assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">31,854</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">19,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Current Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accounts payable, accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Warrant liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">6,944</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;Total current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">9,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3,878</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Operating lease liability - long-term, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Deferred rent - long-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Warrant liability - long-term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">9,762</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5,313</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Total Stockholders' Equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">22,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">14,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total Liabilities and Stockholders' Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">31,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">19,585</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations          (in thousands, expect shares and per share amounts)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Six Months Ended June 30, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Operating Expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">4,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">General and Administrative and depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,533</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,626</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">8,203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">8,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Loss from operations    </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(3,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(5,458</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(8,203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(8,095</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Other income (expense):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Gain from change in fair value of warrant liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,936</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Other expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Interest income, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(1,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(5,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(5,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(7,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Loss per common share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(0.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(0.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Weighted average common shares outstanding - basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">42,393,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">25,888,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">35,765,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">24,617,372</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 9</font><font style="font-family:Arial;font-size:10pt;">&#32;of 9</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20190814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.moleculin.com/20190814" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mbrx="http://www.moleculin.com/20190814" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20190814_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20190814_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20190814_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20190814_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverDocument" roleURI="http://www.moleculin.com/role/CoverDocument">
        <link:definition>0001000 - Document - Cover Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>mbrx-20190814_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.moleculin.com/role/CoverDocument" xlink:href="mbrx-20190814.xsd#CoverDocument" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.moleculin.com/role/CoverDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>mbrx-20190814_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.moleculin.com/role/CoverDocument" xlink:href="mbrx-20190814.xsd#CoverDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.moleculin.com/role/CoverDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mbrx-20190814_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A_label_en-US" xlink:label="lab_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="lab_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2_terseLabel_en-US" xlink:label="lab_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2_label_en-US" xlink:label="lab_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:to="lab_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:to="lab_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99_label_en-US" xlink:label="lab_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:to="lab_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:to="lab_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E_label_en-US" xlink:label="lab_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:to="lab_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:to="lab_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:to="lab_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:to="lab_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:to="lab_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:to="lab_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:to="lab_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1_label_en-US" xlink:label="lab_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:to="lab_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:to="lab_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F_label_en-US" xlink:label="lab_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:to="lab_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C_label_en-US" xlink:label="lab_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:to="lab_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:to="lab_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:to="lab_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:to="lab_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D_label_en-US" xlink:label="lab_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:to="lab_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68_label_en-US" xlink:label="lab_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:to="lab_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871_label_en-US" xlink:label="lab_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:to="lab_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:to="lab_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5_label_en-US" xlink:label="lab_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:to="lab_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mbrx-20190814_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.moleculin.com/role/CoverDocument" xlink:href="mbrx-20190814.xsd#CoverDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.moleculin.com/role/CoverDocument" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_DocumentType_92FCC4A75235E38F57ED97B7CEC17BF2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_DocumentPeriodEndDate_DB855F80016767C433BE97B7CEC11A4D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityRegistrantName_E52AD5C175ADCB92492C97B7CEC15A99" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityIncorporationStateCountryCode_26070B4CA6F315D5A6BE97B7CEC24D9E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityFileNumber_A3AD658B8A44D2199AF097B7CEC2F09E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityTaxIdentificationNumber_8E12022C664F0F45CDE797B7CEC2DD0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityAddressAddressLine1_15C07FA0B376142F379B97B7CEC2AAF4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityAddressAddressLine2_F222F9F4C18E6A5B150097B7CEC23694" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityAddressCityOrTown_00D7598D051EEF39DDC797B7CEC2F25D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityAddressStateOrProvince_2EF894B7BA15DB25427997B7CEC33A2E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityAddressPostalZipCode_5EF4848069ED63D7CCBD97B7CEC39CD3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_CityAreaCode_3047F6686F1D9D8EE5D997B7CEC3BBA1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_LocalPhoneNumber_83A364F39F64159CB4D997B7CEC3F316" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_WrittenCommunications_915F0BB9C2ED4F81222397B7CEC3412F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_SolicitingMaterial_727254CA6CFED80A4AFC97B7CEC4309C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_PreCommencementTenderOffer_68C93BDDA6D6F8375DE997B7CEC412BF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_CA97AB4F6741CB5F645E97B7CEC44A09" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityEmergingGrowthCompany_8760B814662BDEDFED1E97B7CEC4D2A6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityExTransitionPeriod_547655EB47E06378F5E297B7CEC40BCB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_Security12bTitle_4325702C459042F6322C97B7CEC4C70D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_TradingSymbol_F8E16ACAF46BE4F01EBC97B7CEC52E68" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_SecurityExchangeName_F744705B8865714336EC97B7CEC54871" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_EntityCentralIndexKey_0863CB13628B5E42D9FF97B7CEC5C13A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F2AA61A40D06E2FF7C4C97B7CEC10A0A" xlink:to="loc_dei_AmendmentFlag_A6CE3F4FE7D0495C647297B7CEC5D6E5" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>moleculin-logo_horiza03.jpg
<TEXT>
begin 644 moleculin-logo_horiza03.jpg
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M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X #D%D;V)E &3
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M$0,1 #\ O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7S*57L)HY%:GWS6N5S?"CD14Z3+H\ Z(
M
M
M
M
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M\+'.3PEK\K9XRCG:T^.Y4Q"UOH41%<D;TXV5W=I$M)(U\$C&KX#.(YDZH
M
M
M
M
M
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MF]Q!WLYI'2*B?<MXE5&M3H:VC6IL1$0QP/8/%
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MDC3=QU-S1'1)@
M
M
M
M
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M'[^3%<;N9[O$I5J^65[GO=XW.55HG0FY$V(B(>.'H'F@
M                  'TZ:YN,<MJV^QZVLJ*]IIL:RJ+JFG2JNVJK&&ZE^)/
MK;&$ZQ,@S8KZ"6VZTM+B%D1I,C(?C<6UO>0/M;N-DMK(U6O8]J.:YJI16N:Y
M%1R*FQ45%14WG[VUS<V5PR[LY'Q7<3D<Q['*U['(M4<US516N1=J*BHJ+N+!
M?"/S\MMZJ548%RUK['=6 M&W#:V15E%:VW01NO:AVT2^["J-@1HZ>A&<A<.R
M,C4M<J0HB;.I^I7*Q@&.))BF0GLPW%5V_%W56UD7J;1%? J_>H^/<B,8E5+A
M:7<W&8L 6/"-0V/Q3"$HB7+:)=QIUOJK67")]\K)-ZK(]:(6O=%\A-,\EL%A
M['T?L"AV#B<LT-.S*A]Q$ZIG*90^JIR*DFM1;K'+EIIQ*EQ)T=B0E*B5V=ID
M9T4S/E/,63<3=@^9K26TOV[41Z>2]M:<4;T562,54V.8YS>BM30/*F<<LYWP
MIN-96O(;S#W;%5B^4QU*\$C'(CXWHBU5CVM=3;2BH9E'.G2@
M
M
M
M
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M9E2+"\WNHUK5=2WN7;$]P>Y:LD<NZ"1RN6J)&^5:HDV(K<6@
M
M
M
M
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M.8]CDJUS7-54<U46J*BT5#[0^8^H
M
M
M
M
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M
M
M
M
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M%)6V%Q;3W28@UE5#DV%A-?,C43,2%$;>DR732DS[4),^A#\IYX+6%UQ<O9'
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M8-FS!H,P9?G9<X3<LXF/;]A6N1=K7M6K7L<B.8Y%:Y$5%0R0/'/;
M
M
M
M
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MRQ!\6R[A]G8PTHJ00QQ5_?*QJ*Y>E5<JJJ[555,H#Q#W@
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M -]IZ0?&?:
M
M
M
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MU$1$1.I$H?0'Y'[
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MR6NF<MT09S&FH
M
M
M
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MFQ%>ZG%([[Y[G.7I4RV/!.A
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MRKFV;L1%5?72P)1KEWOBX'^4YLKBP(*I%OP
M
M
M
M
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M:B-:B=2(B'VA\Q]0
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MO%K'<6[T5LEM<QT2:"1KD1R*UVUO$C5=&YCZ(CD-CAQYV@
M
M
M
M
M
M                                     'YVHD5AZ3)9C1V9$U;3DQ]I
MEMMZ6MEI$=E<EU"26^MIAM*$FLS-*"(B]!=!_;I'N:UCG*K&[D5=B56JT3HJ
MNW9TG\-CC:YSVM1'NIQ*B)5:)1*KTT38E>C8?H'\']@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\4DP7)^(_',3BMW3N9\7NHJ1->R-SN*>"-BT?(Q.%'*Y>*J)1%5-TA'))P
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M7:Y*THE5V&^(BXED
M                                              Q7NS=FL>.NL<FW
M'N/)ON/UOA_R-]T>1_(V09!\G?=!D%5BU1_Y1BU5=WTOUN^NXK'\!%=\/Q>]
M?:VE:T^YEO+>-9NQJ'+V7H?C&,7''V<?'''Q=G&Z5_ERN8Q*,8YWE.2M*)55
M1%\#-&:,"R9@4^9<RS_%L$MN#M)."23A[21D3/(B8^1:R/:WR6K2M5HU%5-
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M$KCN4KKXWA23.B5_9RQ>Z,1JN;PS1QOV(YNWAHM=BK13.8Y@ZL
M
M
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MN;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I SE--P
M                          I;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWFMD
M9D<Z'>C8>@(/.[X@'%J2HH    !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^<1
MEC.53OJP[Y/=^;2%\49=FLH
M                                                    !%?YUWV9
M/)?^IK_,!JD3CRW=]&#?WOS&Z(#YG^XS'/[G_P PM"@>-4C(H      #IA<4
M?9;XU_0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O(,?>$?8-J
M/I^U[^+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*1HTH,N0      +N7N]WL&
MV_T_;"_%O 1FOS9=Z,?HJ#X2<U&Y.^Z63TO<?!VY.<*R%JP
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M5K&YR4KLJ>Z'F'J@
M        !!C[PC[!M1]/VO?Q;SX6;Y3>]&3T5/\ "0%5.<3NEC]+V_P=P4C1
MI09<@            !T+O*DW@K?? KC_ )1-E%)R#%<6/5F4=5&N0BVUE)=Q
M*(_,7TZ.3+?'*Z!8+5Z>IS/3\;J0R8UURTF5M4L6LHV\-I//\9CZN&Y1)51/
M R1SXT_>&QG+_FE<VZ28/?RNXKRWM_BLO7QVRK"BN\+XVQR+^_ZR1(1&3*
M           %*WWA#?'\X7+K%],5TUUZET#@$&+8Q3<[H[.=;(1"RV\>92DS
M1\?$DX^VL_WQ.-+2?P=!H]RG97_1.0)\Q3-1+G%;MRM7I6"WK$Q%_P#-[=4\
M"HIF+SAYL_3.HL&687*MKA%FU')T)/<\,SU3_P GXNB]-45"!$6E*D
M      3\>[F^VWM+]%?-_K;T>*K<WO=K8^G(?-;TMUR7]Z-_Z G\[L2Z0,Y3
M3<                                 *6_O&7MMZM_17PCZV]X#1KE"[
MM;[TY-YK9&9'.AWHV'H"#SN^(!Q:DJ*     2]^1?]H_J+[U=L_5MD@@#F<[
MGL0_#VOG$98SE4[ZL.^3W?FTA?%&79K*
M
M  17^==]F3R7_J:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\ ,+0H'C5(R*
M     Z87%'V6^-?T Z<^KO'!C-GK_&^,^E;OSB0W"T^_P%@GHBS\WC,_#E3K
MR#'WA'V#:CZ?M>_BWGPLWRF]Z,GHJ?X2 JISB=TL?I>W^#N"D:-*#+D
M "[E[O=[!MO]/VPOQ;P$9K\V7>C'Z*@^$G-1N3ONED]+W'P=N3G"LA:L
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MQ0S)'*M.FC51.O:AN"(^)'
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M;_6WH\56YO>[6Q].0^:WI;KDO[T;_P! 3^=V)=(&<IIN
M                 %+?WC+VV]6_HKX1];>\!HURA=VM]Z<F\ULC,CG0[T;#
MT!!YW?$ XM25%     )>_(O^T?U%]ZNV?JVR00!S.=SV(?A[7SB,L9RJ=]6'
M?)[OS:0OBC+LUE
M                                            (K_.N^S)Y+_U-?Y@
M-4B<>6[OHP;^]^8W1 ?,_P!QF.?W/_F%H4#QJD9%       =,+BC[+?&OZ =
M.?5WC@QFSU_C?&?2MWYQ(;A:??X"P3T19^;QF?ARIUY!C[PC[!M1]/VO?Q;S
MX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER      !=R]WN]@VW^G[87XM
MX",U^;+O1C]%0?"3FHW)WW2R>E[CX.W)SA60M6
M                            :]<D>5&B.).$1M@[\SN-A&/6-BJFI?\
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M$W<NV:5RIJ[A-R]W#9WDJV<O0BMN4[-E5Z$;-V3U5=B<)T%QD^;!@
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MM+]%?-_K;T>*K<WO=K8^G(?-;TMUR7]Z-_Z G\[L2Z0,Y33<
M                     *6_O&7MMZM_17PCZV]X#1KE"[M;[TY-YK9&9'.A
MWHV'H"#SN^(!Q:DJ*     2]^1?]H_J+[U=L_5MD@@#F<[GL0_#VOG$98SE4
M[ZL.^3W?FTA?%&79K*
M                                                17^==]F3R7_J
M:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\PM"@>-4C(H      #IA<4?9;XU_
M0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O(,?>$?8-J/I^U[^
M+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*1HTH,N0      +N7N]WL&V_T_;"
M_%O 1FOS9=Z,?HJ#X2<U&Y.^Z63TO<?!VY.<*R%JP
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M'>)[.%R>!4-QLEYBAS;E+#<S04X+ZRBF5$]B][$5[/&Q_$Q?"U3- YPZ8
M       J ^\9[W^Z3=6FN/-7,=57ZQPV?GV41VE](J\IV%*;AU$64UUZKFTN
M,XXE]M73M2U<&1&9J41: \H65_B>6\1S;.U.UO;AL$:KO[*!*O5%ZGR2<*^&
M+P(9R<Z&;/CN9\,R; Y>QL;9UQ*B;NUN%HQ%3[ID4:.1>A)EIO4K>BX12D
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MQ[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I SE--P
M                            I;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWF
MMD9D<Z'>C8>@(/.[X@'%J2HH    !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^
M<1EC.53OJP[Y/=^;2%\49=FLH
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M;"<-/-/, TRP!<N9<6X=A[KA\RK,]KW\;VL:NUK&)2C$HE.O:;/CBCNP
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MFTC?%<MYBP)RMQNPO;-R+14G@EB5%W47M&MVUV4,<#V#Q0
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MS?ZV]'BJW-[W:V/IR'S6]+=<E_>C?^@)_.[$ND#.4TW
M                "EO[QE[;>K?T5\(^MO> T:Y0N[6^].3>:V1F1SH=Z-AZ
M @\[OB <6I*B@    $O?D7_:/ZB^]7;/U;9(( YG.Y[$/P]KYQ&6,Y5.^K#O
MD]WYM(7Q1EV:R@
M                                           $5_G7?9D\E_ZFO\P&
MJ1./+=WT8-_>_,;H@/F?[C,<_N?_ #"T*!XU2,B@      .F%Q1]EOC7] .G
M/J[QP8S9Z_QOC/I6[\XD-PM/O\!8)Z(L_-XS/PY4Z\
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M45*HI=S"L6PO';"/%<&N(;K#9DJR6)[9&.3=L<U51:+L5*U145%HJ'K1\!Z
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M][M;'TY#YK>ENN2_O1O_ $!/YW8ET@9RFFX
M        4M_>,O;;U;^BOA'UM[P&C7*%W:WWIR;S6R,R.=#O1L/0$'G=\0#B
MU)44     E[\B_[1_47WJ[9^K;)! ',YW/8A^'M?.(RQG*IWU8=\GN_-I"^*
M,NS64
M                                   BO\Z[[,GDO_4U_F U2)QY;N^C
M!O[WYC=$!\S_ '&8Y_<_^86A0/&J1D4      !TPN*/LM\:_H!TY]7>.#&;/
M7^-\9]*W?G$AN%I]_@+!/1%GYO&9^'*G7@
M
M        &!-R\6>.7(2,Y'W5I37&QG5M(91;9'B]:_D<1IM/8A-;E+++&25?
M:CXI'&EM'V^CX!U.7<\9ORF]'Y;Q*\LVUKPQR.2-5^^B55C=_":IR.9<A9+S
MBQ69GPNRO7*E..2)JR(GWLJ(DC/X+T(:=]^[O\9,V;EV.A-A9WH^Z63ZXU+<
M+_G.P4E>ER/&;C7,RLS2&2E'X:GW+F;V(Z*)I:DF2[$Y6YM\Z8:K8<TVEKB=
MMLJ]G^S3>%:L1T*]:-2%E5V<2(NRM.;>3;(V*-=-E*\N\*NMM&/_ -J@\"4>
MYLR=2N69]$HO"JHM8/\ D-Y)_.[0Z)UK4X!!WGB<0UJ*\TM-D9-:DQV*=:\?
M YL.JSI<DVD&3B8<"<RVX7;XRNJ#79;*7,CI?FA6P3W;L,OW>PO$2-M=VR=J
MN@I7=QO8JIMX4VTJUG'E?U8RFC[BWLV8KA[?YRR<LKZ;TK YK)ZTW\$;VHNS
MB6J*L4%K4VM%93:>[K;"FMZV0Y$L:JUAR:^R@2FC[78TV#+;9DQ9#:O0I"TI
M41_"0G:">"ZA;<6SV26[TJUS51S7(NY4<E45%ZT4K[<6]Q:3.MKICXKABT<Q
M[5:YJIO1S51%14ZE2I\\?J?B                  &V'%7FSR-X:94>2Z-S
MR53P)DIF3D>"7*7+G7N8):)I"F\BQ=U]EAR0XPT313HJXEFRUU2S):ZF.$SS
MIME#42Q^)9FM6R2M:J1SL\B>*M?Y.5$5:56O Y'1JNUS'$@Y U0SIIIB'Q[*
MMVZ.%SD62!]7V\U*;)(E5$K1*<;%9*U-C7M+@O [SE>/G+MRFU_G1QM';VG&
MS"CXED-FVYB&9V"B)"4X%ETE,5EZ=+<Z>'53DQYQK63<<YG:IP9^:H\N^;,@
M))BN%\6)Y7;55EC;[K"W^OB2JHU.F5G$RB5?V=40T>TFYELGZBNBP?%N'"LU
MOHU(9'>XS._J)EHBN5=T4B-DJO"SM**I,6*]%D@
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M);@;5I]2TTA;BOD/4V(4U&EHE=2;2SD=^WD^;M>"A1D79:))77JHC,DF5B\
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M1J5DK42S6[RE?PW+FMJ^+:R>/H]TA?21J5V(_A5CE]:YQLX.*.Z
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MYC6H?9XYCBR6&4%6J/HG;7*(M%2!';&LWHLSD5M=C&OV\-9-:N9' M-NTP#
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MJ9FYFS7F+.6*OQO,]W->8E)O?(M4:E57@8U*,C8BJO"R-K6-KL:AB<>Z<\
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MBIL5%1=J*B[%1=Q>V.2.:-LL3D=$Y$5%145%14JBHJ;%14VHJ;%0_0/X/[
MH=>>A]H_MW[U=3?5MC8U$Y8^Y[#_ ,/=><2&37-7WU8C\GM/-HR(03^5S
M  )^/=S?;;VE^BOF_P!;>CQ5;F][M;'TY#YK>ENN2_O1O_0$_G=B72!G*:;@
M       !ROQN&8'       7<O=[O8-M_I^V%^+> C-?FR[T8_14'PDYJ-R=]
MTLGI>X^#MR<X5D+5D5_G7?9D\E_ZFO\ ,!JD3CRW=]&#?WOS&Z(#YG^XS'/[
MG_S"T*!XU2,B@      .F%Q1]EOC7] .G/J[QP8S9Z_QOC/I6[\XD-PM/O\
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M%V0
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M$7Z?M;?C)"$<ZO\ ==C_ **N/@U).T7[VLN^E[;X1IT;1D$;1D6WG)Z)/>O
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MPS5K+'Q]J,@S%:\++NW1?6/5%X98T55<L,M%5BK56N1\:JY6<3I#A$A,@
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M3SS7,S[FY>Z2XD<KG.<JN<YSEJYSG+55<JJJJJJJJJU4_"/T/R
M     +#'DV^:E9:0R?'^+/(3)Y$O2656$6GUKF5].-Q&G\AFN&S#I9TV3W+C
MZXOYCB&C[UE'I9*B?_@XKDI;=2^8?0Z',ME+GC*<"-S) Q7W$+&_^[C3:KVH
MF^X8E5V)Q3-\GRGHQ%N-RU:^S96OH<A9QG5V5[AZ,MII'5^)R.V-8YR[K:15
M1-J\,#O*\F-9%;<H&>!I6 !0Z\]#[1_;OWJZF^K;&QJ)RQ]SV'_A[KSB0R:Y
MJ^^K$?D]IYM&1""?RN8    !/Q[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7
M)?WHW_H"?SNQ+I SE--P        Y7XW#,#@      +N7N]WL&V_T_;"_%O
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M96%-B[H
M          ?/M:FJO:R?2WE;7W-/:17X-G4VL.-8UEC!DMJ:DPY\"6V]%F19
M#2C2MMQ"D+29D9&0_6">>UF;<VSWQW#'(YKFJK7-<FU%:Y**BHNY46J'XW%O
M;W<#[6Z8R6VD:K7,>U'-<U=BM<U45%14V*BI12!'FCY"6B=R(N<VXPV$/0.Q
MY!OSON.<8D2]-7\M2%J**W4Q4.VFO#??-/1VL3)KX[:32BMZJ[TVFTYYILSY
M=6/#<ZL=BN#I1O:U1+N-.OB6C;BB=$G#(Y=JS;*+4C4WE)RIF5)<4R(]N$8T
MM7=C15LY%ZN!*OMZK3;%Q1M38D&VJ53.27$KD#Q*R]6&[VUU<X?*><=*EO?#
M*QQ#*8[2E?ZWC&50?&I[=LT))2VD.E)CDHB?::7\47HR=GW*F?</_2.5[R.X
M8B)QL];+$O5)$ZCV=2*J<+M[7.3:4 SMIYG#3S$OT9FRREMI%5>"3UT,J)TQ
M2MJQ_6J(O$W<YK5V&N [ XH               ^QC^07V)WE3DV+W5KCF1T-
MA%MJ.^H["557%/:074OP[&LLH+K$R#-BOH);;K2TK0HB,C(Q\]W:6M_;265]
M''-9RL5KV/:CF/:Y**US7(J.14V*BI13Z;.\N\/NH[ZPEDAO87H]DC'*Q['-
M6K7-<U45KD7:BHJ*BENCRRO.YH]IJH-$\Q;FIQ39"VXU5B&Z97JM/B>?2B-+
M,>LS@FTL5F(Y=)(R\*:1,U4]9&A117S:1)H+K1RUW.!I+FC3V.2?!ZJZ6S2K
MY8$WJZ'>Z6).EFV5B;4XV\2LT3T-YH[7'UARGJ3+';XW1&0WJT9%<+N1L^YL
M,R]#_)BD78O9OX4?9 %/BZH                     $&/O"/L&U'T_:]_%
MO/A9OE-[T9/14_PD!53G$[I8_2]O\'<%(T:4&7(    !NGY<GMY<1?I^UM^,
MD(1SJ_W78_Z*N/@U).T7[VLN^E[;X1IT;1D$;1GS;FGK,AI[:@NH;5C37E;.
MI[:O?[O G5EG%=A3X;W8I"_"DQ7UH5T,CZ*]!D/VMKB:TN([NV<K+B)[7M<F
M]KFJBM5/"BHBGX7-M!>6TEG=-1]M*QS'M7<YKD5KD7P*BJBG,YY&:?M= ;XV
M[I:X0\4O6FP,GQ-E^1VFY8559:2&Z*X2:4H)3-W2''F-GVI,VWTF:4GZ"V:R
MAF"#->5\/S';JG9WMI'*J)[%SFIQL\;'\3%\+5VJ8>9TRY<90S;B.6+E%[2Q
MO)8D5?9,:Y>S?XGLX7INV.38AA<=&<P   $BGE1;N+0W/;C[DTR5ZK099E7\
MU63][B68RJK9T=S$8;\YY?1+,*GR.Q@6#BC,B24/JH^WJ(CUURU^U.EF+64;
M>*[@@^-1]*\5LO:JC4Z5?&U\:)]_LVDS<OV:?V2U;P>^D=PV=Q<?%9>A."Z1
M845R]#62.CD5?O-NPZ%@R8-BP    "M3[QQO?Y#U7H_CG5S'6YN?959;.RMB
M.OL+[G,(B*I<>A3T]2-Z+<9!D+TAM)$9$]4$I70R3UN3R@97^,XYB>;YVHL5
MK VVB5?Z29>.16]2LCC1J^"6G64BYTLV?%< PK)=NY4EN[AUU*B?T<"<$;7=
M:/DD<Y/##5>@J*B_1G6   ']XT:3-DQX<.._+ERWVHT6+&:<?DR9+[B6F(\=
MAI*W7GWG5DE"$D:E*,B(NH_E[V1L6214;&U%555:(B)M555=B(B;U/[8Q\KT
MCC172.5$1$2JJJ[$1$3:JJNQ$3>=*/AQHUOC9Q<T9I#L:1/P'7M+ R(V$MI8
M?S&R0N^S>8R31J1X4[+[6<\GXRC,G/2I1]5'CAJ'F9V<<[XGF6JK%=7;W1UW
MI$WR(46O2V)K$Z-VY-QMOIME5N2<AX5E:B)+:6;&R4W+,[W2=4IT.F>]4W[]
MZ[S98<:=N5-?>5?X[\2OO5V[\[X +X<F_P"K,>_#VOM)S/?G=_6F7OD]Y[>W
M*Q(NF46     )^/=S?;;VE^BOF_UMZ/%5N;WNUL?3D/FMZ6ZY+^]&_\ 0$_G
M=B72!G*:;@ 89Y";WP'C/IO/=W[,GKA8C@-*Y:3&HYLG8V\]UUN%2X[3-/NL
MM2+K(KB2Q#B(4M"#>>2:U)02E%T64\KXKG/,5KEK!F\5_=2<**M>%C415?(]
M4151D;$<]RHBK1%HBK1#F<XYLPC(^6KO-../X<.M(E<J)3B>Y51K(V(JHBOD
M>K6,151.)R55$JJ<[+E9R>V5R]W9EN[=H3C<ML@DG'HZ&.^ZY385BD1UWY"P
M_'VG"03573QG3(U]J7)<E;LE[N?><4K7+(N2L&T_RW;Y:P1M((FU>]41'S2J
MB<<LB]+GJF[<UJ-8VC6HB8T9_P ]8YJ-FBXS1CKZW$SJ,C155D$2*O9PQIT-
M8B[Z5>Y7/=5SG*NN0Z\XL     _97U\^VG0ZNJ@S+.SL9+,*OKJ^,]-G3IDE
MQ+4>)#B1D.2),F0ZLDH;0E2EJ,B(C,?G++%!$Z>=S60L:JN<Y41K43:JJJ[$
M1$VJJ[$/UAAFN)6P6['/G>Y&M:U%<YRKL1$1*JJJNQ$3:I*7I3R7?,"W5!@W
M2-2P]5X_8L-OQ+?<F0P\,D*0XVEU)/XBPW<[!@GX:TG_ *Q4-),U=",S2HDP
MAF3F,THRY*ZW6_=?7;%HK+2-9DZMDJ\$#OX,J_NI6>LK\LFK^9XF7*8<W#[-
MZ51]Y(D*[=NV%$?<-_A0I^XM-P8ONXG+)<1M<W=?'>/.-"C=CQ;'94R(A9*5
MV);FNZ[@O.(4DB,U&PDR,S+H?3J<?/YP,AI(J1X;BZQ="JVW1?L)<.3_ ,2D
MCQ\EFH2QHLN*8,DO2B.N53^,MNU5_BH:\;6\B3S M9P95E3XEK_<$2$R4B1_
M-3G*)<[PB;)QSU6FSJJP.[LGFC^+X,6,\\M7_AH67I'78%S/Z48S*V&XN+O#
MY'+1/C4-&U\+X73L:B];G(B=*H<;F#E/U@P.)T]M;V>)1M2J_%)ZNITT9.R!
M[E3=1K7*O0BD2V983F.NLEM<-S_%<BPG+:.0<6XQG*Z:PH+ZKD$1'X4ZJM(\
M6;&6I)DHN]!=R3(RZD9&)YP[$L.Q>S9B.%3PW-A*E621/;(QR=;7-56KZBE>
ML3PO$L&OI,-Q>WFM<1B6CXI6.CD:O4YCT1R>JAY<?:?      >MP/.LNUCF>
M,;"P*^L,8S/#;J!D.-W]6\;$ZKMJU],B+(:5Z4+1WI[7&UDIMYM2D+2I"E)/
MX,4PNPQK#I\)Q6)D^'7$;HY&.2K7-<E%1?\ Z*FU%HJ*BHBGHX3BV(X%B<&,
MX1,^#$[:5LD<C5HYKVK5%3_ZHM45*HJ*BJAT(O+KYLXUSGX[TFRHJ(M5L+'7
M6L3VYBD<S0FBS6)#8?=G5S+CCCQXUDT5Q,VO<,UDE*W(ZEJ>C/=,G-7=-KS3
M'-TF#/XI,)F19;65?9PJJHC7+N[2-?(D39M1'HB->TV'T9U0L=5<FQ8W'PQX
MQ"J17<2?S<Z(BJYJ;^RE3RXUV[%5BJKF.-\1%Q+( %+?WC+VV]6_HKX1];>\
M!HURA=VM]Z<F\ULC,CG0[T;#T!!YW?$ XM25%     )>_(O^T?U%]ZNV?JVR
M00!S.=SV(?A[7SB,L9RJ=]6'?)[OS:0OBC+LUE  CS\R[F]4\&N.%UG,)ROF
M;9S)<G$=-X]-\)]$S*WXW?)R2P@*<2[)QW"H3A3)9$78\\<:*I39RDK*6M&=
M-)]3<X1X9*CVX#;TENY$JE(D79&UVY))E\AO2B<<B(O J$.:X:I6^E62I<5B
M5CLPW-8;.-U%K*J;9'-WK'"U>-_0KN"-53M$5.?/DV2Y!F>17N799<V.19/D
MUM87V0WUO*=G6ES<VLIV;96=A,?4MZ3,FRWEN.+49FI2C,:P65G:8=:16%A&
MR&RAC:R-C$1K6,:B-:UJ)L1$1$1$,>[Z^O,3O9<1Q"5\U]/(Z221ZJYSWO57
M.<Y5VJKE5555Z3X8^D^4     D$XW^5WS9Y25<#)M<Z;LJG!;)#;T'/]AS(N
M!XM81'NGA6%*N\4S=9/6K])>L54*<SW)4DU=Q=!%&<-;=-LD3NLL8Q%DF)LV
M.@MT6>5JIO:_@JR-WWLKV+TTH3!DK0?5#/D#+[!<-?'A3Z*VXN')!$Y%W.9V
ME'RM^^B8]NQ4K4D,J?=R.7,F$V]<[BX[U4U?12H42WV/:I90I"%$EV4K75<C
MUA"S4E:4)6V1IZI6HC$2S\WV062*VWP_%WQITJRW;7Q)\8=LZJJB]:(3';\E
MNHKXD=<XE@T<J^Q1]R^GC7XNW;UT14ZE4Q-LGR!.?&#PI,_&6-0[;0RAQY$#
M <_D5]NXRA;O1)Q=C8_@4(Y?A-DHVFI+O4UDE"EJZD/>P?FJTLQ.1(KU<0L%
M79Q3P(YE=G3;R3K2NRJM3=541#GL;Y0]7,*B=-8IAV(HFWAM[A6OIMZ+F.!M
M:;:(Y=]$55(CMHZAVEI+*I.$;=U]EVM\LBMI?<H<QHK"BGN17#,F9T1$YAI,
M^ND=I^%)8-QATBZH69"?,$S!@F9+%,3P"[M[RP<M..)[7MKTM7A5>%R=+74<
MG2B%=\>RYCV5[]V%YBL[BRQ!J5[.:-T;E3H<G$B<35Z'-JU>A5,<CUSQ0
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M5.O- _-,^SVY7?17/^<ZL2KH?WLX%\N;[5Q$6O?<[F#T>[VS3G=C6XQK
M   Z(GE9_9[<4?HK@?.=H,D=<.]G'?ESO:M-E-!.YW+_ */;[9QOX(J)=*FO
MO*O\=^)7WJ[=^=\ %\.3?]68]^'M?:3F>_.[^M,O?)[SV]N5B1=,HL
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MQH2S;W%O=PMN;5[);=Z5:YCD<UR=:.1514\**?0'Y'[
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MUS;7MM'>6<C);25B/8]CD<Q[')5KFN:JM<UR*BHY%5%1:HM#Z0_$_<
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MZVOH3<BCN/DB4N'+V1E-9*0MFVKV[1AV/40GT^ XN.Y+<0X@XBA2SF1UNO\
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M^0L6TVS==94Q;RY(51T<J(J-FA?MCE:FVG$FQS:KP2->SB56JIK(.T.&
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M1S=:AOS#G6/)5A)7!\';[HB>M?>2)5ZK38O91JV)*[6/69.E2 D6H*B@
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M,!Q_&<L8K%C> W$EMBD#JL>Q=OA146J.:Y-CF.16N38Y%38>+F'+N"9KPB;
M<PVT=UA,[:/C>FQ>I45*.:]J[6O:J.:M%:J*E3G\>8KPFR#@MR)N=8/2)MUK
MZ_B%EVILMF(:)^]PR;)>83"LUQR*.G(L9GLN09R22V;IMMR4MMM26DC5K2+4
MFTU.RC'C34;'BT3NRNHDK1DR(BU;7;V<C51[-]*JQ55S'*9 ZS:7WFE.<Y<"
M<KI<'F;VUI,ZE9(7*J<+J;.TB<BL?NK1'HU&O:AH:)1(F     )*/*3Y#2..
MG.O3%W(G.1,5V/;%IG-VR6:&'Z/8LF'5U3TQ7<E"8=+FC=58NJ41DE$,_P#V
MB'->LI,S?IAB-LUJ.OK./XW#UH^W17.1/"^'M8T\+T)MY>,XOR7JOAET]ZMP
M^]D^)3]2LN51K%=X&3)%(O@8IT&!D^;"%#KST/M']N_>KJ;ZML;&HG+'W/8?
M^'NO.)#)KFK[ZL1^3VGFT9$()_*Y@    $_'NYOMM[2_17S?ZV]'BJW-[W:V
M/IR'S6]+=<E_>C?^@)_.[$ND#.4TW        #E?C<,P.       NY>[W>P;
M;_3]L+\6\!&:_-EWHQ^BH/A)S4;D[[I9/2]Q\';DYPK(6K(K_.N^S)Y+_P!3
M7^8#5(G'EN[Z,&_O?F-T0'S/]QF.?W/_ )A:% \:I&10      '3"XH^RWQK
M^@'3GU=XX,9L]?XWQGTK=^<2&X6GW^ L$]$6?F\9GX<J=>:!^:9]GMRN^BN?
M\YU8E70_O9P+Y<WVKB(M>^YW,'H]WMFG.[&MQC6      !T1/*S^SVXH_17
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M27,;$LEDFRG?<3K65VUS%:OEV\BIO?&BHK741)&*CD3B1Z-BZ$VD#@
M7O?(NV8YL/R\]>U,F24N;JC,]@ZSE/&[XCQ-Q[O[MJF-(+O5X1P:#.(C#2>B
M>D=ML^A]>X\ON9S!4PG5J[N&)PQW]M!<HE-FUG8O5.OBDA>Y5V^4J^)-8N5/
M''8SHY9V[W<4N'W-Q;*M:K1']NQ%ZN&.=C439Y*)XUF#%?2QX
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M\TNG46<].Y<=M&(N.X(CKABHFUUO1/C,:^#@1)DV5XHD1*(YQ1:&G)E,
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MR'>XR\)-W;"JIZZ[+[:@3KS GV'/"FM9=G[Q8Y$L:]?>CMFXY6RY=LD^OH*
M9D2CZ).5=%<I-SIJ5AN$SLX\/CE^,3HNU%B@3M%:[P2.1L2_O^C>1%KKG)V1
MM+L4QFW?P8C)#\7@5%HY)KA>S1S?OHVJ^5/P?3N.=V-;C&L     R7IC6EMN
M?;VK]142C;M]G; Q# H#Y-FXF)(RN_@4B9SR2]"8T IIO.J49)0VVI2C))&9
M>-F+&8,N8!>X_=;;>RM)9W)UI$QS^%/"ZE$3>JJB)M/<RS@=QF;,=AEVTV7-
M]>0P-7?199&LXE\#>+B5=R(BJNPZ9F#X9C>N<,Q/7^'5C%-B>$8Y2XGC53&2
M26*ZBQ^NCU55#;Z$74H\**A/4_2HRZGZ3&,>)XC>8QB,^+8@]9+^YF?+(Y=[
MGR.5SE]5553<;"L,LL%PRWP?#6)%A]K R*)B;FQQM1C&^HU$0]2/A/O
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M>V:<[L:W&-8      '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?\
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M4J.3X9>GI7U=%^2:_=)E?',+55X(;^&5$Z*S0JQ?L]@E=G0F_HLFBG)=H
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MLZUZT]5*G<X69781IG#@,+J3XK?QL<G7# BS/^Q*V!*=3M_0M)X:1&7X
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M3IE]3[%0><O %Q#3RRQZ)M9<.Q%J.7[F*X8YCE]65L">KOZZ8(T6,S
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MQ34ZUNK:^MH[VRD9+:2L:]CV.1S'L<E6N:Y*HYKD5%14545%JA]0?@?N
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M4VM5-J;=QX69N975#-N 766\8ELG89>1+'(C+=K7*U51=CD78NS>15"<B 0
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M+\6\!&:_-EWHQ^BH/A)S4;D[[I9/2]Q\';DYPK(6K(K_ #KOLR>2_P#4U_F
MU2)QY;N^C!O[WYC=$!\S_<9CG]S_ .86A0/&J1D4      !TPN*/LM\:_H!T
MY]7>.#&;/7^-\9]*W?G$AN%I]_@+!/1%GYO&9^'*G7F@?FF?9[<KOHKG_.=6
M)5T/[V<"^7-]JXB+7ON=S!Z/=[9ISNQK<8U@      =$3RL_L]N*/T5P/G.T
M&2.N'>SCORYWM6FRF@G<[E_T>WVSC?P142Z5-?>5?X[\2OO5V[\[X +X<F_Z
MLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918     WL\L:MC6OF <3(LLEFTUN3&
M;)'8:2/UFF4_<0C,U)6784R"V:BZ=33UZ&1^DHPUIF?!I3CSX_7+ATC?4?1B
M_N.4EC0N!EQJ_EZ.3UJ8E$[U65>W]UJ'14&19LR        '.+\Q.-'B\[^7
MC49EMAM7(3:<E2&DDA*I$S++*9+>,B]!N2)3ZW%G\*EJ,S^$:_Z1O?)I?E]S
MU55_1-LFWJ2)J(GJ(B(G@0Q9UF8R/5C,;6(B-_3%TNSK=*Y57U5557PJ:9B1
M"-     "U![L]_SK?].'_'D4>YS/^F_^(?[B7YY'O^J/^&_[^6H!1TOP
M              &H//S3+G(#AER.U1%CG+ML@UC=V>-PR3WG,R_##8SC#8GP
MEV%*RK&X;9K+J:"5W$E1EVG(&E68DRIJ+@^.O7A@BO6-D7JBFK#,OJ12/6G3
MNJF\CG5W++LX:9XUE^-.*XFL7NC3KFAI/"GJRQL2O1OHNXYOHV#,5
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M;ADS-G]8W@^QY6WP5)3T1MOC6KF78MFS%8'[=WN;NT^SY.SJ6AT81D.;/
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M_6WH\56YO>[6Q].0^:WI;KDO[T;_ - 3^=V)=(&<IIN        '*_&X9@<
M     !=R]WN]@VW^G[87XMX",U^;+O1C]%0?"3FHW)WW2R>E[CX.W)SA60M6
M17^==]F3R7_J:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\PM"@>-4C(H
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M_.M_TX?\>11[G,_Z;_XA_N)?GD>_ZH_X;_OY:@%'2_
M  !S?^?>B?\ #9S%Y :@CQ40Z2@S^QML1CM-^&PSA&9-1\SPR,ST-3;GJ.-7
M\6.X:3Z>,RLNB3(TEL'I7FC]L=/<*S ]W%<RVC6RJN]9H56&95_?2,<Y/ J;
M]YBKJ[E/]B=2<8RXQO#:PWCGPHB;$@F1)H43][%(UJTZ47=N33\2 1P
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M=F/2K,+L$QMO:6CZNM[EK52*XC1?7-JJ\+VU1)(E571N5-KF.8]VFXD,C4
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M;S*LTR*N]>%[U8BK[%J)1$1$3<L1V26   %37WE7^._$K[U=N_.^ "^')O\
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ML%MJKE5/CSF,S=8M:R[C2B<?0RY8GW$M/*1$I'(CFT1O KI1!"1/
M  !!C[PC[!M1]/VO?Q;SX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER
M  ;I^7)[>7$7Z?M;?C)"$<ZO]UV/^BKCX-23M%^]K+OI>V^$:=&T9!&T8
M !SZ?-ST2>@N?&\J:'!.%C6PKEG<F)]&TLL/UNRDN7=V4)A!FAB#6YS\KP&4
M)Z(0B(1))*>B2U?T"S1^U6EF&7$CN*\M(UM)>E4=;^0RJ]+G0]D]57:JNVU7
M:8^<Q.4_V1U<Q6VC9PV-Y*EY%T(K;FKW\*=#6S]M&B)L1&;$1-A&J)D(1
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M?>5?X[\2OO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918
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M2OB3AJO@J2CHG<_%-6\NRU1*XM;LV[O='I'3QKQ43PT.C,,A3:
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M2/IG"ORNW_M!_E]GWZ$Q?\CN/[,?X4>4GYM>_O['-B?R<#]NLD?3.%?E=O\
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MS/\ IO\ XA_N)?GD>_ZH_P"&_P"_EJ 4=+\                    &FOF
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M,F!9MP>''LN7,5WA,[:LD8NSPM<BT<Q[5V/8]&O8M4<U%2ADL>,>X
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ME-R_==2^(]_*F*)@>:<-QI5HEGB%O/7J[*9DE=Z?<]:>,Z=@Q8-T@
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M6PI;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWFMD9D<Z'>C8>@(/.[X@'%J2HH
M  !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^<1EC.53OJP[Y/=^;2%\49=FLI0
M6\Z[%GL8\R/?SBD.)B9.SK3*:Y3OBFIUFPU;AL2<LE+89;6VF\KY:$>&;B4H
M2235WDLBU0Y;[YM[H[A2)3M(%N(G4IL5MS,K>E?8.:JUHM5K2E#(WF?L'6.M
MF+N5%[.=+:5M:[4=:PH[H3V;7HE*I1*5JBTBH$YD      $SGD*RH\?S#<1:
M>=0VY.UGM"+$0H_2_(11(FJ:;]'I642&ZY__ %08KKS2,>_26X<U*HV]ME7P
M)QTK]E43U2S/*5(QFLENURT<^QND3PKV?%3["*OJ%Z09C&K
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M !^';LJJ=-"UG)U.L.K,L:.1O:X/<-IL\JDMN^B?Q.+9MHU>BI=N&;!J*
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MARIUYH'YIGV>W*[Z*Y_SG5B5=#^]G OES?:N(BU[[G<P>CW>V:<[L:W&-8
M    '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?]'M]LXW\$5$NE37
MWE7^._$K[U=N_.^ "^')O^K,>_#VOM)S/?G=_6F7OD]Y[>W*Q(NF46     -
M_/*T^T)XH_2I7_-MF(KUO[IL=^0N]LTEW03OBR_Z0;[5QT1!D@;*
M!SDO,;]O+EU]/VR?QDFC7W2#NNP#T5;_  :&+FM'>UF+TO<_".-+!(Q&(
M !:@]V>_YUO^G#_CR*/<YG_3?_$/]Q+\\CW_ %1_PW_?RU *.E^
M             *'GG6\4CXV\R<BRF@K/4M;\A&IFU<67'84U7PLFF33:V3CC
M*C,F_6(.3/%9>$TE+4>'<Q6TD7;T+4/EOSU^V.G<-C=/XL8PE4M9:K5RQHE;
M>1? Z-.SJNUSXGJN\R;YG]/_ -B=2IK^TCX<$QA'7<5$HULJNI<QIT5;*O:T
M38UDT;4W$00L 5R                           W4X4\[]Y\&=A%EVK;@
M[+$[A^.G/M6W<F0O#,Z@,D:$G,C([U5&0PFU&<*UBI3+C'U0KQ8SC\=Z.-2-
M+\L:FX3\0QN/@OXT7L+EB)VT+EZE]G&[V<3O)=O3A>C7MD[3#5G->E6,_I'
M9./#Y%3XQ:O5>QG:G6GL)&^PE;Y;=R\3%>QUZSAKS<TAS>UJWGNI;KP;>M1$
MC9UKRX=CLYE@=Q(9)SU.W@MK,Y=5)62RA6;!*AS4MK)"DNMO,M9AZB::YETT
MQE<+QZ.MN^JPW#$589V(N]CNAR;..-WELJE45JM<[5S335'*VJ6")BV7I:7+
M*)/;O5$F@>J;GMZ6+MX)6U8^BT5'-<UNX C\D<
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M)2W]XR]MO5OZ*^$?6WO :-<H7=K?>G)O-;(S(YT.]&P] 0>=WQ .+4E10
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M;MYPFJ&*,P73C'<3>M%BPFZ5NVGEK"]L:5VTJ]6I6BTKN4YKPV.,20
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M>V:<[L:W&-8      '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?\
M1[?;.-_!%1+I4U]Y5_COQ*^]7;OSO@ OAR;_ *LQ[\/:^TG,]^=W]:9>^3WG
MM[<K$BZ918     W\\K3[0GBC]*E?\VV8BO6_NFQWY"[VS27=!.^++_I!OM7
M'1$&2!LH        '.2\QOV\N77T_;)_&2:-?=(.Z[ /15O\&ABYK1WM9B]+
MW/PCC2P2,1B     6H/=GO\ G6_Z</\ CR*/<YG_ $W_ ,0_W$OSR/?]4?\
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MUX!JUA'N7#;9IMXT6YM57=T++"J[7PN7IVNC549)O:Y\D AXFL
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M[E%<\:E81EY[>*S?=-DGZNP@K-,BKN3B8Q6(J^R<U**JHB]',9 &TH
M%37WE7^._$K[U=N_.^ "^')O^K,>_#VOM)S/?G=_6F7OD]Y[>W*Q(NF46
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M'*N1'91LI$_3V-(L:HB^5':(ON[U1-R2[(&HJ4<CI51:QJ4BAI29<
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MVSG;1HMQ;HM$>B43MX*K5T3EIQ-JKH7*C7*K58]\I@A GL
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MJJO2ILE;V\%I;LM;5C8[:)C6,:U*-:UJ(C6M1-B(B(B(B;D/H#\C]@
M   "#'WA'V#:CZ?M>_BWGPLWRF]Z,GHJ?X2 JISB=TL?I>W^#N"D:-*#+D
M   W3\N3V\N(OT_:V_&2$(YU?[KL?]%7'P:DG:+][67?2]M\(TZ-HR"-HP
M    *D7O'FBBJ-CZ(Y&5D4DQLTQFVU5E;S+*D(1=8=+7D6+RI;I?$=F6]/D4
MUA)GT43-41>DB+I?;D_S/\8P?%,H3.\NVF9<Q(J^PF3LY$1.A&/C8J]%93/#
MG3RI\7QK"<Z0-\BZ@?:RJB>SA7M(E5>E7LD>U.FD2%9P7-*.@       !:%]
MV_T,F9?[^Y,6L$E-TL&GTQA<QQHG$'/MEQLQS\VE++MCS($"'0(2M'5:F9[J
M3-*3,G*3\X.:5CM<*R9 [;(Y]Y,E:>2VL4%>M'.6=:+LJQJ[5W7NY*LI))=X
MOGBX9Y,3&64+J5\I])KBG4K6I;HBIMI(Y-B;[78HH:!@      5-?>5?X[\2
MOO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918     GX]W-]MO
M:7Z*^;_6WH\56YO>[6Q].0^:WI;KDO[T;_T!/YW8ET@9RFFX %1OW@OA=(QC
M.<>YG8-4]<;SWY,PC<3<-DNVJSBNA^JXCEDI+9&:8N4T$)->^Z:4MM3*YGN4
MIV:DA?GE/U&9>X9-IUB<G^V6O%-:57UT+EK+$GAB>O:-3:JLD=1$;&IG;S@Z
M9/L,5AU,PJ/_ &*[X8+SA3UD[6TAE6G1+&WLW+L1'QMJJNE0K1BY12
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MOWM$9$[\,GC2T'*9DUV9-4&8W.SBP[!H'3N5?6]L]%BMVK]]57S-\,*^);R
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MXXHUK<6LS4M:UJ,U*6I1]3,_29B9$1&HC6I1$(155<JN<M7*?X'^G^
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MRG;C;DI*V,:IF9:]K&6VH>7LLL(-<J]P"*CME&HC4]2%U[B* VVY;[EAU:3
M\033S'Y:81=R5M'N79#.Y:K$JKN9.NUO0DW1[JJI2WFNT;7'\-74G+L5<9LX
MT2\8U-LUNU*),B)ODMTV.Z5@Z?<FHM/8:"F<
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ML6L9LY,<DJ3)CQ=3M&]8,*U0P5&2*R#-=M&GQF#=7<G;0HJJKH7+O2JNB<O
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MS/\ IO\ XA_N)?GD>_ZH_P"&_P"_EJ 4=+\
M'\W6FI#3K#[3;S#S:VGF74)<:=:<2:'&G6UDI#C;B%&2DF1D9'T,?ZUSF.1S
M55'(M45-Z+UH?XYK7M5CT16JE%1=J*B]"E';SBO+:E\2-FO;GU11OJXX[1N9
M#S$>#'6J)JG-I[CLN5A4OP^Y,;'+3X[]&ZKM2ELG(9EW1VUOZ8<O>L4>?<%3
M+F.RI^U]C&B*KEVW4+:(DR=<C=C9DV[:2;GJC<L.9+1.33O'%S-E^)?V+OY5
M5$:FRTG=55@7JC=M= NRB<4>]B*^$P62*O
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MDY+,I+<8QBV=KAGN5M"VTA54V+)*J23*GWS&,C1?O9EZRVP*%&AH
M5-?>5?X[\2OO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918
M  GX]W-]MO:7Z*^;_6WH\56YO>[6Q].0^:WI;KDO[T;_ - 3^=V)=(&<IIN
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MBS-G=T5_FEBH^*)OE6UJY**CDXD19IFKM1ZHC&+ZQKG-;(3YBK!;@
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M6     -_/*T^T)XH_2I7_-MF(KUO[IL=^0N]LTEW03OBR_Z0;[5QT1!D@;*
M       !SDO,;]O+EU]/VR?QDFC7W2#NNP#T5;_!H8N:T=[68O2]S\(XTL$C
M$8@    %J#W9[_G6_P"G#_CR*/<YG_3?_$/]Q+\\CW_5'_#?]_+4 HZ7X
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M+=[9()&HYKFJCFN:Y*HYJI5%145%146BIM0_8/S/T
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MD:C4PF1G>$1_CD23)*NF.D?H[NI]>TK-Y;YPZ-;%F_"*NV5ELY/LT@F7U?\
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MVGN3,RV>:<+O,9DQ"RF22-LLMLZ-7(BI1Z,M&.5-O0]J^$F:%=2RX
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MNJWQ+]H8+&'XAVW9_%F2LKV_9<?'VLTU:=BWAX>&E75K5*2[I7HOE;2'X_\
MLU<8A/\ I'L.T^,OA?P]AVW!P=E!#2O;.XN+BK1M*46N_@BHET
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M:BI'<1HOKF[^%[:HDL2JKHW*FUS',>[382&1J
M       6Q/(=\Q%R^@0^$&X;TW;>EARI?'S(+25WO6%%"9?G6^K'Y#QDXX_C
M\9IR92DI2S]0)^(DT-Q8C2J)<T6D:6LKM2\O14MY'(E_&U-C7JJ-9<HB=$BJ
MC)MWE\,BU5\CDT&Y3=977<+=+<R2UN(FJN'R.7:Z-J*Y]JJKTQHBOAW^Y\4:
M4;'&U;/@I27K
M
M
M
M
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MF<OQ:[:B]G,U/8NW]G,U/7Q*JJF]JO91RZ'"4")@
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MR)-G!.U$7C:F](YDI)'O1*NCXE=&Y3?D162X
M
M
M
M
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ME/)C6#))?Y)<ZJ2HE9;9%78RY:U-R>M;.B(QRTXDC<Y&K#L+"%;@
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MJ*;#03PW,++FW<U]O(U'-<U45KFN2K7-5-BHJ*BHJ;%0_:/S/U
M
M
M
M
M
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M7PMG%;*[?)9U1.!.M;=ZHWH]R?&UJ48Y2P^*DER0
M
M
M
M
M
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MM0R /)/8
M
M
M
M
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M"CKJSJNYBJB7$*=2->YLS&IM7CF=N0M"BDQ>\
M
M
M
M
M
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M"T7:G0M47:A[,><>F
M
M
M
M
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MO5J<#&(C$<YW B\2M1:<2HB4V/''G:@
M
M
M
M
M
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M*5\I5Z-GBV'2V>&X=A[>&PMX(&TI2-C6)15JJ>2B=.WQ[3T@^,^T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
<                                 #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>form8-k63019earningsre_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20190814.xsd" xlink:type="simple"/>
    <context id="D2019Q3SD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2019Q3SD"
      id="Fact-FF67BFF477A671CFC2D88BB5B714C551-wk-Fact-FF67BFF477A671CFC2D88BB5B714C551">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2019Q3SD"
      id="Fact-1BB182FCC8EFE2752BCC8BB549360B06-wk-Fact-1BB182FCC8EFE2752BCC8BB549360B06">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2019Q3SD"
      id="d3968466e93-wk-Fact-BFCCCD59C0DB907A9DD68B8898B81256">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2019Q3SD"
      id="d3968466e110-wk-Fact-335E36ED6114A3EF098697945A4E7BF0">2019-08-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2019Q3SD"
      id="d3968466e119-wk-Fact-C4D13C33BD86A112EF278B8A40761BD3">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2019Q3SD"
      id="d3968466e142-wk-Fact-D876CC2F066E8A9CDD0C8B8B3D88DBE8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2019Q3SD"
      id="d3968466e147-wk-Fact-18E6E7AE14006870306F8B8B7C83F55B">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2019Q3SD"
      id="d3968466e152-wk-Fact-0B7AC34A141D86976BAB8B8BC12CE89B">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2019Q3SD"
      id="d3968466e173-wk-Fact-E01AEC1750693A148DCC8B8CD136E90E">5300 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="D2019Q3SD"
      id="d3968466e178-wk-Fact-C170B3D425448F1927EE8B8D22349C41">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="D2019Q3SD"
      id="d3968466e183-wk-Fact-F002B16F19FFE4D0DE7E8B8E2105341A">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2019Q3SD"
      id="d3968466e188-wk-Fact-57270FDF7DA81601812C8B8E35D5ABEF">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2019Q3SD"
      id="d3968466e193-wk-Fact-ABD734054327A766E1A48B8E47662411">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2019Q3SD"
      id="d3968466e206-wk-Fact-D1503B64D913FBA947A48B8F4C5852BD">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2019Q3SD"
      id="d3968466e211-wk-Fact-4FA8854297B8F32F64CA8B8FB6060C92">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2019Q3SD"
      id="d3968466e234-wk-Fact-836A8E11FDADC5973A6A8BA16FC3308E">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2019Q3SD"
      id="d3968466e243-wk-Fact-1610C2D8BA4212E5B3BE8BA18C6F9946">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2019Q3SD"
      id="d3968466e251-wk-Fact-35A648C7A9643729A4AD8BA1A1F302BB">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2019Q3SD"
      id="d3968466e259-wk-Fact-D2D1EF654FD44F6B14708BA1BA93BA32">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2019Q3SD"
      id="d3968466e274-wk-Fact-1DC4D24253C6E897F2238BB69D203995">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="D2019Q3SD"
      id="d3968466e282-wk-Fact-F26AB43F0BE91CB21A658C470D9EFCAA">true</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle
      contextRef="D2019Q3SD"
      id="d3968466e317-wk-Fact-EB0A622A2D08A339A3E58BA4B8ABEB86">Common Stock, par value $.001 per shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2019Q3SD"
      id="d3968466e322-wk-Fact-35D5D1C56CCC9AAD50F68BA4FA6FD3D4">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2019Q3SD"
      id="d3968466e327-wk-Fact-E202F2E157FA5A6250428BA65A4B008C">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6622990592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Document<br></strong></div></th>
<th class="th"><div>Aug. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 16,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $.001 per shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_B[ +QN[L/S8^"\H6?MV%_ )02P,$%     @ 3XH03YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M-XJ<[O9GJ,6@WLX%][]$\0-02P,$%     @ 3XH03]CM!]TY 0  *P(   \
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MK%T(]NY?R23^GF/XI_D/4$L#!!0    ( $^*$$__P"8(O0   (4"   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.MDD$*@S 0 +\B>4!7;>FAJ*=>
MO+;]0-#5B)J$[);J[YMZ44&A!R\)8</,0)(\L)/<&$VJL10,?:<I%8K9W@"H
M4-A+.AF+VD\JXWK)_NAJL+)H98T0A^$5W)(ALF3)#/(R%2XO(Q&\I*N14P%#
M!Q_C6E*(3#!MT<D+_)71XC]Z4U5-@7=3O'O4O%$Q"P1L!\5S$"GIL'RR:W1-
M1X>LX'LQYT4,CQT>7S%1]_276<]>@C"MA[_)1/TUP.K795]02P,$%     @
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M_,W(1TKM05\-_\GR"U!+ 0(4 Q0    ( $^*$$\?(\\#P    !,"   +
M          "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $^*$$\GZ(<.
M@@   +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ 3XH03Z3#3U/O    *P(  !$              ( !F0$  &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 3XH03YE<G",0!@  G"<  !,
M             ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !/BA!/EW1_&;@"  !D#   &               @ 'X"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 3XH03SG?*?U] @  @P8  !0
M             ( !Y@L  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%
M  @ 3XH03[JA.8K7 0  ,@8   T              ( !E0X  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !/BA!/V.T'W3D!   K @  #P
M@ &7$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 3XH03__ )@B]
MA0(  !H              ( !_1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ 3XH03PN/V ,A 0  5P0  !,              ( !
M\A(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @  1!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="form8-k63019earningsre.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.moleculin.com/role/CoverDocument</Role>
      <ShortName>Cover Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k63019earningsre.htm">form8-k63019earningsre.htm</File>
    <File>exh991-financials63019q220.htm</File>
    <File>mbrx-20190814.xsd</File>
    <File>mbrx-20190814_cal.xml</File>
    <File>mbrx-20190814_def.xml</File>
    <File>mbrx-20190814_lab.xml</File>
    <File>mbrx-20190814_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moleculin-logo_horiza03.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k63019earningsre.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "mbrx-20190814_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mbrx-20190814_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k63019earningsre.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20190814_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20190814_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20190814.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.moleculin.com/20190814",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form8-k63019earningsre.htm",
      "contextRef": "D2019Q3SD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Document",
     "role": "http://www.moleculin.com/role/CoverDocument",
     "shortName": "Cover Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form8-k63019earningsre.htm",
      "contextRef": "D2019Q3SD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.moleculin.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001659617-19-000145-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001659617-19-000145-xbrl.zip
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MK%\_2/\ J[T92,!C/AS"VP&%E7Z;P6L+N3"+0*GJ$W6% K8S0@2F[T4=A:!
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M4+;/0S2@<;T#8(KIVP9CIW;-:):"XDS"*Q$B8I&:6!CR*#18S98+GF'0G=X
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M]RMXC !XA40B"OP&^S/*L1O;G\*=@H@/3&]?L#8+,X]H+V%O-) !@"I =S,
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M)7@Y=0 .<T=M@YWVC VLCP?CIP&:0C2Q'6>MVX JGK,T8]^'I:!#'Q71\LY
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M;I'(42#(Q,L2DRT'> ;6<SEI#OT^V@\8)=AB 1.BC6,>)2PR". M*+3(.H]
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MSX6\G8XZ;-F"W,O$?BNPOQF-B;NT\-I*[P*(H-UL'3@L<%C0FJ7XT6%!U;#
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MC^:[+X#^_=O[S:[R1Q_^_GYSD(;!A_\'4$L#!!0    ( $^*$$\OYL>3&1<
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M<=P503[HM651%#;&+,NJ)VN>JXFB8LF>+YB&9NJFHEJ*!]F@P#+F]S0.>W6
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M559$B\L>!WZ]**ZSN_3)S/DI WO,TB]?NKY^!&NVFJ/JDB[XKJ^[EB%J@FA
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M<1?@PF4'<.-#W1NW_BV\"BN,Y;(6R<S?R&:%H9;S<DN>4T<G?P%02P,$%
M  @ 3XH03_"E$3PZ 0  >@(  !4   !M8G)X+3(P,3DP.#$T7V-A;"YX;6R=
MDDUO B$0AN_^"DK/++O:0]>XFM9>3+87C='KRHXN<0$#Z-)_7\!J8VJ3IA<^
MAF?FY1T839QHT0FTX4H6.$M2C$ R57.Y*_!R05X6T]D,3\:]T0,AZ]=YB=X4
M.PJ0%DTU5!9JU'';H%4-9H^V6@FT4GK/3Q4AYR04%RV7^V$8-I4!Y P?&M:
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MVX]"]-(%MDR'M["%&^ZYN-L\H TD?#0L#FEWD??*1ZS0!=#H*/:W(]]0\-*
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MBY"]P&X84,TM2U&$AP^>)U[-_B6.J&O5Z>0D'<+'K6;K+/>KU0F4)NMZQZO
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MMLA7'_TZ6/82CVO:7YR!6]NJ2#.NCOM=)Y-I>LH B4/_^I-;8S8V>%*AL.G
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M5%V8T@Y=XHFB6K04,TQ3&94GCOQS]<<_GX]M:;8//XTSRVR G6"RV@Q63^M
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MU&4_ST2ZJYW3!-A)"4/GVI:2L!3)HV2GDYR<?,+/+5QDJ5.DH)2I0R+*Z,I
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MBXEKP:''QCGO4PGLT]L(.LSN[([Q@$EB5@W)YU4B2I<A#KBUJ-MG+77;7<%
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MQ1;AM0AM]/MAE3YI?1\*[EV3E;O<N"RK/K&TV>4NM-%=(QB=IPY@MC)2F]"
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M#/2=O+!!304HT <X#A57P0-4]\.<-W#88RPM2Q-'+>HL=DPR\1XS?DOG5+
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M>%E2116)<=WY%$))IKN!YDQ8VYU[*1<XI&L R;@'M$FY(4BL)*%Q$TQ8<8E
M'6NR:5%3%VPP6]D.9; 957H/BZ6M2-JAQV^KEU4ES88W"K1@+:#DE7%#!KE>
M'/LQRBH8,"IO*),ZK(D.-!78^YA[^]WMQLT>TV)17G)OM$@:DT+J[!DW4 [3
M)D"MUO.>L_RPXL)WJOA[2?"*$DNG&50Y=%]K0?U9<[;"^MN::1XD['EI^.-Y
M0R-U*F"T8@7<-5?K'S?]HO,6=8!R'6TOZ.D$S>"S-5<5>AXZ/U>#J#HUDVSU
M> P5Q&A82=AV&05@COWKX/7^=O6L]?0'_8GCQ,<AXTH6%H5ED#MLXS_9GT3
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M?AJ3?OBW,>&YH*=?>YSI"[T XI2A8:6:VE\UEF4'S_Y%6^+J[.H1!<SQ IE
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MJQ3=G&\)?5Y_-SQZH_>CXHA9)O0PBN@MICIIX&>'QA?P,GLG_!Z\>8NFCP
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M;_O4V:?F=4M0CBA521H5H.B>:R[B<7(FE5KW?^FV[Z]=QD O^OBW+C7'#5_
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MI_R+W"HO86#94FP')2QDKML=;Z(P_H%;G[=^I)-I9:'9O)[-8 M3.$&'2IJ
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M3S,&K@&C:<K)5_V2U,3/% Q;9+/TV6H2>/+D]-F.*M3"S?O00H2_<=PR^!?
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ME@GF4P[Z8;%C8-3ZRH2L:HGR2NQQ%04'[+@8*L(^B("(",'A\$T9@MU)LFL
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M45CP)6>('Y_C=N2YV=:VT#7 IZRXD<K_Z-LE>: ?]_VZ\DV"_M&\>2':DVL
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MTOA^P4^P#)I6P&DV%,N*SRL)#_@+GHJ%@Z'/HCQ*0Q5*O8.%J8)PP"CWC,S
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M*=C4U R%RA@RSS4ON#:GD7?RMW]38 4BZC'3;J3@3NTMU8]V/$4A050_6H0
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M)^+;+:P5'WGQU94I6S&7K*@]_(&HJ?RLLE+2)!;CXIF7MU7AYA]O@> 8:N^
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M LK8!E *\?["<JEF+EIIMXX3YM0WW$U=JN99H/I.[7+G00SWD^[W;M2]!'W
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M6HK'AF49V].[=AELD82CHG)?4WM.7)U8SR%;@G"T[*, X+-TZ^)CG#<6[K&
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M"D0:'9_ S>ETS6 ):OB6?8%S4-L?_W,*Z;>:(,.@Z(DG<=Y?>QY9L@KY]'I
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MG?KF;(S"U"K[RL,$G2X[KAMMXKNY 4/FR,]R:QPM W!)0=L%+9QR+1^:'63
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M>=6";QY%,<&-8%S>VNK%/29??%7[)\+%R.Y$S'T5TB,2OWR7KGZ\19-1/7R
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MK!#ZHM;'KWD$>B)' OW/)N7B!DQ&@_;$N(RW+'J)LKMSX1D4_]))O[.\[]]
MU+V%OD^O>]'JVLE@$" XO^9 VJ>J,KY ===:>;$[B586P'@**TI>9/LO(Y?!
M\WYF?8)SR<Y+J>/O*CXGC6]R'B_PQ=H2$1?!)?XP<^[U2@-A6V'30I<XN[&9
MQ<8 [@4.NJ ?/80UIB<%F-W*5PK\=@YVE'\\&ZG_LV7L?_&_^%_\25"YFOD_
M4$L! A0#%     @ 3XH03]BH%!C%-   \[0" !X              ( !
M &5X:#DY,2UF:6YA;F-I86QS-C,P,3EQ,C(P+FAT;5!+ 0(4 Q0    ( $^*
M$$\OYL>3&1<  /Z$   :              "  0$U  !F;W)M."UK-C,P,3EE
M87)N:6YG<W)E+FAT;5!+ 0(4 Q0    ( $^*$$_:4;>$1@,  &01   1
M          "  5),  !M8G)X+3(P,3DP.#$T+GAS9%!+ 0(4 Q0    ( $^*
M$$_PI1$\.@$  'H"   5              "  <=/  !M8G)X+3(P,3DP.#$T
M7V-A;"YX;6Q02P$"% ,4    " !/BA!/]JX2[)\!  #,!0  %0
M    @ $T40  ;6)R>"TR,#$Y,#@Q-%]D968N>&UL4$L! A0#%     @ 3XH0
M3[M3CS$S"@  W6X  !4              ( !!E,  &UB<G@M,C Q.3 X,31?
M;&%B+GAM;%!+ 0(4 Q0    ( $^*$$_D9O$?GP8  #\Y   5
M  "  6Q=  !M8G)X+3(P,3DP.#$T7W!R92YX;6Q02P$"% ,4    " !/BA!/
M^?ZY\9VR 0 $!P( &P              @ $^9   ;6]L96-U;&EN+6QO9V]?
B:&]R:7IA,#,N:G!G4$L%!@     (  @ * (  !07 @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
